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alcolm R. Bell, MBBS, FRACP, Ryan J. Lennon, MS, Verghese Mathew, MD,
andeep Singh, MD, David R. Holmes, MD, Charanjit S. Rihal, MD
ochester, Minnesota
bjectives The purpose of this study was to evaluate secular trends and factors associated with
ajor femoral bleeding after percutaneous coronary intervention (PCI) in routine clinical practice
uring the past decade and to assess the impact of these complications on outcomes including
ortality.
ackground Signiﬁcant changes in patient demographic data, adjunctive pharmacotherapy, and
ccess site management have occurred during the coronary stent era. Trends in major vascular com-
lications after PCI during this time have not been well characterized.
ethods Consecutive patients who underwent transfemoral PCI from 1994 to 2005 at the Mayo
linic (n  17,901) were studied. Patients were divided into 3 groups: Group 1 (1994 to 1995, n 
,441); Group 2 (1996 to 1999, n  6,207); and Group 3 (2000 to 2005, n  9,253).
esults The incidence of major femoral bleeding complications decreased (from 8.4% to 5.3% to
.5%; p  0.001). Reductions in sheath size, intensity and duration of anticoagulation with heparin,
nd procedure time were observed (p  0.001), and multivariate analysis conﬁrmed each as an in-
ependent predictor of complications (p  0.001). Adverse outcomes of major femoral bleeding in-
luded prolonged hospital stay (mean 4.5 vs. 2.7 days; p  0.0001) and increased requirement for
lood transfusion (39% vs. 4.7%; p  0.0001). Major femoral bleeding and blood transfusion were
oth associated with decreased long-term survival, driven by a signiﬁcant increase in 30-day mortal-
ty (p  0.001 for both).
onclusions We noted a marked decline in the incidence of major femoral bleeding after PCI over
he past decade. Mortality associated with these bleeding complications and with blood transfusion
emains a signiﬁcant issue. (J Am Coll Cardiol Intv 2008;1:202–9) © 2008 by the American College
f Cardiology Foundation
rom the Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester,
innesota. Dr. John W. Hirshfeld, Jr., served as Guest Editor for this paper.anuscript received August 10, 2007; revised manuscript received November 26, 2007, accepted December 21, 2007.
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203ince the introduction of coronary stents in the late 1980s,
ignificant changes in the anticoagulation protocols have
esulted in varying rates of stent thrombosis and bleeding
omplications (1–9). The impact of these changing trends
n bleeding after percutaneous coronary intervention (PCI)
nd its relationship to adverse cardiovascular outcomes is
ess well studied. To address the hypothesis that changes in
CI practice have altered the incidence of major femoral
leeding complications and that these complications have a
linically meaningful impact on morbidity and mortality, we
tudied a cohort of 17,901 consecutive patients treated with
CI from 1994 to 2005.
ethods
ajor vascular complications among 17,901 patients under-
oing transfemoral PCI from 1994 through June 2005 were
dentified with the Mayo Clinic PCI database. In this
atabase, major vascular complications are recorded pro-
pectively at the time of hospital dismissal. For the present
tudy, patients were divided into 3 groups on the basis of the
ear they underwent PCI: Group 1 (1994 to 1995, n 
,443), the early stent era with intensive anticoagulation and
ntiplatelet regimens during and after PCI including war-
arin, dextran, prolonged intravenous heparin, aspirin, and
ipyridamole; Group 2 (1996 to 1999, n  6,212), a period
f transition from intense anticoagulation regimens to dual
nti-platelet therapy with aspirin and ticlopidine and initial
se of periprocedural glycoprotein (GP) IIb/IIIa inhibitors;
roup 3 (2000 to 2005, n  9,253), the contemporary era
ith routine use of aspirin and clopidogrel, frequent use of
P IIb/IIIa inhibitors but reduced intensity and duration of
nticoagulation with unfractionated heparin. Low molecular
eight heparin and bivalirudin are not used in our PCI
ractice.
Upon completion of the PCI procedure, the femoral
heath is sutured in place and connected to a flush system.
n obturator 1 French size smaller than the sheath is placed
ithin the sheath to permit elevation of the head of the bed
y 45° (increasing patient comfort) while waiting for the
ctivated clotting time (ACT) to fall. When the ACT is
elow 180 s the sheath is removed, hemostasis is secured
ith manual compression for 10 to 15 min, and the patient
emains lying flat in bed for 2 h. Between 2 to 4 h after
heath removal, patients can lie on their sides in bed.
etween 4 and 6 h after sheath removal the patient is
llowed to sit upright in bed and is then allowed to ambulate
fter 6 h. This protocol has not changed significantly during
he study period.
Institutional review board approval was obtained for this
tudy. Patients who denied research authorization to their
edical records were excluded, as required by State of
innesota statute (n  335). Interventions with brachial oradial artery access were also excluded. ceﬁnitions. The primary end point of this study was major
emoral bleeding complications after PCI, which included
ny of the following: femoral hematoma, femoral bleed, and
etroperitoneal hematoma. Significant femoral hematoma
as defined as 4 cm in diameter that required blood
ransfusion, surgery, or prolonged hospital stay. Femoral
leed was defined as external bleeding from the femoral
rtery requiring blood transfusion or surgery. Retroperito-
eal hematoma was identified with abdominal ultrasound or
omputed tomography scan. Blood transfusion was defined
s the administration of whole blood or packed red blood
ells within 7 days of PCI. Severe renal impairment was
efined as creatinine 3.0 mg/dl, on dialysis or previous
enal transplant. Peripheral vascular disease was defined as a
istory of claudication or peripheral vascular surgery (in-
luding non-traumatic amputation) or angioplasty. Myocar-
ial infarction (MI) before PCI was diagnosed if 2 or more
f the following criteria were met: prolonged chest pain
20 min, cardiac biomarker elevation 2 times the upper
imit of normal (creatine kinase, creatine kinase-myocardial
and, or relative index), ST-
egment T-wave changes, or
ew Q waves on serial electro-
ardiograms indicative of myo-
ardial damage. Procedural suc-
ess was defined as 50%
esidual stenosis in the treated
egment and no in-hospital
eath, Q-wave MI, or emer-
ency coronary artery bypass
urgery.
tatistical analysis. Continuous
ariables are summarized as
ean  SD unless otherwise
oted. Discrete variables are presented as frequencies and
roup percentages. Missing values were not included in the
enominator for percentage calculation. Kaplan-Meier es-
imates were used to describe long-term survival. Group
istributions were compared by 1-way analysis of variance or
earson’s chi-square test or the log-rank test. All tests were
-tailed with a 0.05 type 1 error rate, except for multiple
esting situations. A Bonferroni adjustment to a 0.025
ignificance level was used when Groups 1 and 2 were
ompared with Group 3. Multiple logistic regression was
sed to estimate partial associations between clinically
elevant risk factors and the combined bleeding end point.
on-linear associations between continuous covariates and
he end point were inspected. The continuous covariates
ith non-linear associations were then collapsed into groups
or ease of interpretation. Generalized estimating equations
ere used to account for correlation between different
rocedures on the same patient assuming an exchangeable
Abbreviations
and Acronyms
ACT  activated clotting
time
BMI  body mass index
CI  confidence interval
GP  glycoprotein
MI  myocardial infarction
OR  odds ratio
PCI  percutaneous
coronary interventionorrelation structure.
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204Multiple Cox proportional hazard models were used to
stimate the partial hazard ratios (HRs) between those who
id and those who did not have a bleeding complication or
blood transfusion. Follow-up analyses were restricted to
he first PCI/unique patient within the study period. The
roportional hazards assumption was assessed by plotting a
catterplot smoother through scaled Schoenfeld residuals.
iolation of the proportional hazards assumption was han-
led by allowing for separate effects at different follow-up
ntervals. Age was treated as a time-dependent covariate (in
-month intervals) to allow for a nonlinear association.
ther risk factors in the model were gender, urgency of
CI, pre-PCI shock, pre-PCI MI, body mass index (BMI),
moking status, congestive heart failure on presentation, left
entricular ejection fraction, diabetes, severe renal impair-
ent, peripheral vascular disease, American Heart Associ-
tion/American College of Cardiology type C lesion, num-
er of diseased coronary vessels, prior coronary bypass
urgery, and prior PCI.
esults
atient characteristics. The majority of patients treated
ere men, with no significant change from Group 1 to
Table 1. Changes in Clinical and Procedural Characte
Gr
199
(n 
Age (yrs) 64.4
Men 1,74
Diabetes mellitus 53
Hypertension 1,37
Hypercholesterolemia 1,21
Body mass index (kg/m2) 28.6
Moderate/severe renal impairment 9
Peripheral vascular disease 27
Unstable angina 1,80
Myocardial infarction 24 h prior 31
Type of PCI
Elective 78
Urgent 1,24
Emergency 40
Sheath size (F) 8.2
Venous sheath 31
Glycoprotein IIb/IIIa inhibitor 2
Peak ACT (s) 405
Mean systolic blood pressure (mm Hg) 137
Mean diastolic blood pressure (mm Hg) 74
Duration of procedure (h) 1.7
Heparin use post-procedure 1,95
Vascular closure device
*p 0.001 versus Group 3.ACT activated clotting time; PCI percutaneous coronary intervention.roup 3 (72%, 70%, and 70%; p  0.05). Mean age rose
rom Group 1 to Group 3 (64.4 years, 65.9 years, and 66.9
ears; p  0.001). The proportion of patients treated for
cute MI (occurring 24 h before PCI) also rose from
roup 1 to Group 3 (13%, 14%, and 19%; p  0.001).
hanges in other patient characteristics are detailed in
able 1.
rocedural characteristics. Procedural characteristics are
ummarized in Table 1. Mean sheath size decreased signif-
cantly from Group 1 to Group 3 (8.2-F, 7.8-F, and 6.4-F;
 0.001), and concomitant use of a venous sheath also
eclined between these time periods (13%, 12%, and 6%;
 0.001). Use of GP IIb/IIIa receptor blockers rose
ignificantly from Group 1 to Group 3 (1%, 41%, and 58%;
 0.001). Use of individual agents in Groups 1 to 3 was
s follows: abciximab 1%, 39%, and 18%; eptifibatide 0%,
%, and 38%; and tirofiban 0%, 1%, and 2%. Intensity of
nticoagulation with heparin decreased from Group 1 to
roup 3, as assessed by peak intraprocedural activated
lotting time (405 s, 339 s, and 312 s; p  0.001;
emochron assay) and by use of post-procedure heparin
nfusions (80%, 36%, and 27%; p 0.001). Mean procedure
uration decreased from Group 1 to Group 3 (1.7 to 1.4 h;
s of Patients Undergoing PCI
5
1)
Group 2
1996–1999
(n  6,207)
Group 3
2000–2005
(n  9,253)
7* 65.9  11.9* 66.9  12.2
) 4,354 (70%) 6,474 (70%)
)* 1,381 (22%)* 2,408 (26%)
)* 3,774 (62%)* 6,573 (75%)
)* 3,679 (65%)* 7,072 (84%)
* 29.0  5.2* 29.7  5.6
215 (3%) 323 (4%)
) 705 (12%) 904 (10%)
)* 4,087 (66%)* 5,120 (55%)
)* 878 (14%)* 1,704 (19%)
) 2,521 (41%) 2,875 (31%)
) 2,623 (42%) 4,578 (49%)
) 1,056 (17%) 1,797 (19%)
* 7.8  0.9* 6.4  0.8
)* 719 (12%)* 563 (6%)
2,536 (41%)* 5,328 (58%)
* 339  79* 312  61
136  29* 131  27
71  12* 68  12
* 1.4  1.0* 1.4  0.9
)* 2,215 (36%)* 2,456 (27%)
315 (5%) 433 (5%)ristic
oup 1
4–199
2,44
 11.
9 (72%
1 (22%
2 (57%
6 (57%
 5.1
1 (4%)
6 (11%
9 (74%
9 (13%
9 (32%
8 (51%
2 (16%
 0.7
2 (13%
7 (1%)*
 110
 27*
 12*
 1.3
5 (80%
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205 0.001). Vascular closure devices were first used in
roup 2 (5% of patients; Angioseal 1.9%, Perclose 3.1%),
nd use remained low in Group 3 (5% of patients; Angioseal
.8%, Perclose 3.2%). Mean systolic and diastolic blood
ressure during the procedure declined from Group 1 to
roup 3 (137/74 mm Hg, 136/71 mm Hg, and 131/68
m Hg; p  0.001).
n-hospital outcomes. Procedural success was obtained in
4.4% of all patients. In-hospital mortality was 1.9%. Use of
ntracoronary stents rose from 34% in Group 1 to 89% in
roup 3, whereas use of atherectomy fell from 12% in
roup 1 to 2% in Group 3 (p  0.001 for both). The
ombined incidence of in-hospital death, Q-wave MI,
mergency coronary artery bypass surgery, and stroke fell
rom 5.7% in Group 1 to 2.6% in Group 3 (p  0.001).
ajor femoral bleeding complications. A significant reduc-
ion in the incidence of major femoral bleeding complica-
ions was observed over time (Fig. 1); complications oc-
urred in 8.4% of patients in Group 1, 5.3% of patients in
roup 2, and 3.5% of patients in Group 3 (p  0.001).
ignificant reductions were observed for all individual
leeding complications (Table 2); femoral hematoma, fem-
ral bleed, and retroperitoneal bleed all declined by at least
0% from the earliest (Group 1) to the most recent (Group
) time period.
Rates of blood transfusion declined significantly from
roup 1 to Group 3 (8.5%, 7.8%, and 5.6%; p  0.001)
Table 2). This change was driven by a decrease in the
requency of large-volume blood transfusions of 3 or more
nits (Group 1 4.5%, Group 2 3.2%, Group 3 1.8%;
 0.001). There was no significant change in the
Figure 1. Changing Incidence of Major Femoral Bleeding Complications
From 1994 to 2005
The incidence of major femoral bleeding declined signiﬁcantly from thet
earliest (8.4%) to the contemporary time period (3.5%).requency of small-volume blood transfusions of 1 to 2 units
rom the earliest to the contemporary time period (4.0% vs.
.8%; p  0.05). Among patients with major femoral
leeding, 43% did not require a blood transfusion; 60% of
atients with major femoral hematoma did not require
ransfusion. In addition, 72% of patients who required
ost-PCI transfusion did not meet the definition for major
emoral bleeding.
ultiple regression analysis. A multiple regression model
as used to identify variables independently associated with
he composite end point of any femoral bleeding complica-
ion (Fig. 2). Sheath size above 6-F was identified as a
trong independent predictor of major femoral bleeding
p  0.001) (odds ratio [OR] 1.38 for 7- to 8-F, OR 1.65
or 9-F, OR 2.48 for 9-F). The absolute risk of compli-
ations by sheath size was as follows: 5-F  2.4%, 6-F 
.2%, 7-F 4.2%, and7-F 6.3% (p 0.001 for trend).
ther predictors of major femoral bleeding included age
65 years (in particular those 75 years [OR 2.64; 95%
onfidence interval (CI) 1.98 to 3.52]), female patient (OR
.64; 95% CI 1.38 to 1.94), severe renal impairment (OR
.29; 95% CI 1.69 to 3.08), GP IIb/IIIa inhibitor use (OR
.54; 95% CI 1.29 to 1.84), peak activated clotting time
OR 1.47; 95% CI 1.16 to 1.87), use of post-procedure
eparin (OR 2.29; 95% CI 1.93 to 2.73), and procedure
uration (OR 1.19; 95% CI 1.07 to 1.32). Use of a vascular
losure device was associated with increased risk for major
emoral bleeding (OR 1.58, 95% CI 1.09 to 2.29). Patients
ith mildly (25 to 30 kg/m2) and moderately (30 to 35
g/m2) elevated BMI exhibited lower risk for complications
hen compared with patients with BMI in the normal
ange (OR 0.76 for BMI 25 to 30 kg/m2, OR 0.75 for BMI
0 to 35 kg/m2). Diabetes (OR 0.80; 95% CI 0.67 to 0.97)
as associated with lower risk for major femoral bleeding
omplications (p  0.023). Peripheral vascular disease was
ssociated with a trend toward lower risk for these compli-
ations (OR 0.79; 95% CI 0.62 to 1.01, p  0.063).
ssociation of major femoral bleeding with outcomes. Pa-
Table 2. Changing Incidence of Major Femoral Bleeding and Blood
Transfusion After PCI
Group 1
1994–1995
(n  2,441)
Group 2
1996–1999
(n  6,207)
Group 3
2000–2005
(n  9,253)
Femoral hematoma 172 (7.0%)* 236 (3.8%)* 257 (2.8%)
Femoral bleed 60 (2.5%)* 76 (1.2%)* 54 (0.6%)
Retroperitoneal bleed 20 (0.8%)* 19 (0.3%) 26 (0.3%)
Blood transfusion 207 (8.5%)* 482 (7.8%)* 516 (5.6%)
1 to 2 U 98 (4.0%) 288 (4.6%)* 347 (3.8%)
3 U 109 (4.5%)* 194 (3.1%)* 169 (1.8%)
*p 0.005 versus Group 3.
PCI percutaneous coronary intervention.ients who had major femoral bleeding after PCI had a
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206ignificantly longer post-procedure hospital stay than pa-
ients without vascular complications (mean 4.5 days vs.
ean 2.7 days; p 0.0001). Blood transfusion was required
ore frequently after a major vascular complication (39.0%
s. 4.7%; p  0.0001).
Patients experiencing major femoral bleeding had signif-
cantly higher mortality during long-term follow-up. This
ifference was driven by significant excess mortality in the
rst 30 days after PCI (HR 14.2; 95% CI 9.95 to 20.3, p 
.01); the risk of death was not significantly different
etween patients with and without a major femoral bleeding
omplication after 30 days (HR 1.10; 95% CI 0.95 to 1.28,
 0.20). Excess 30-day mortality remained significant
fter adjustment for baseline patient and procedural char-
cteristics as described in Statistical Analysis (adjusted HR
.96; 95% CI 6.94 to 14.3, p  0.001). When analyzed
ndividually each of the 3 major bleeding complications
ere independently associated with decreased long-term
urvival. This was driven by significantly increased 30-day
ortality, as follows: major hematoma (adjusted HR 12.8;
5% CI 6.60 to 24.8, p  0.001), major femoral bleeding
adjusted HR 10.7; 95% CI 7.34 to 15.7, p  0.001), and
Figure 2. Multiple Logistic Regression Model Odds Ratio Estimates for Any
Advanced age, female gender, and renal disease predicted increased risk. Proc
closure devices, and intensity/duration of anticoagulation with heparin. The pa
ted as dots; lines indicate the 95% conﬁdence intervals (CI). BMI  body mas
onary intervention.etroperitoneal hemorrhage (adjusted HR 43.8; 95% CI M6.4 to 75.1, p  0.001). For all 3, the effect of the
omplication on mortality after 30 days was non-significant.
aplan-Meier curves in Figure 3 demonstrate worse long-
erm survival for patients with: (panel A) any bleeding
omplication versus no bleeding complication, (panel B)
etroperitoneal bleeding versus no retroperitoneal bleeding,
panel C) major femoral bleeding versus no major femoral
leeding, and (panel D) major hematoma versus no major
ematoma. Over time, 30-day mortality associated with
ajor femoral bleeding seemed to decline (Group 1 HR
6.1, 95% CI 8.8 to 29.5; Group 2 HR 9.8, 95% CI 5.4 to
7.9; Group 3 HR 6.9, 95% CI 3.5 to 13.4), although this
rend did not reach statistical significance (p  0.065).
Blood transfusion within 7 days of PCI was associated
ith increased mortality at 30-day follow up. This risk was
ose-dependent, with transfusion of 3 or more units inde-
endently associated with greater risk (adjusted HR 18.1;
5% CI 13.7 to 24.0, p  0.0001) when compared with
ransfusion of 1 or 2 U (adjusted HR 8.9; 95% CI 6.3 to
2.6, p  0.0001). Excess mortality associated with blood
ransfusion persisted through long-term follow-up: Kaplan-
r Femoral Bleeding Complication
l predictors included sheath size, use of glycoprotein (GP) IIb/IIIa inhibitors,
dds ratio (OR) point estimates for the risk factors listed on the left are plot-
x; BP  blood pressure; MI  myocardial infarction; PCI  percutaneous cor-Majo
edura
rtial o
s indeeier estimated long-term survival for patients receiving: 1)
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207o post-PCI blood transfusion; 2) 1 to 2 U blood transfu-
ion; and 3) 3 U blood transfusion is shown in Figure 4.
iscussion
he main findings of this study were: 1) there has been a
ignificant decline in rates of major femoral bleeding com-
lications after PCI in the contemporary era; 2) this
ownward trend in adverse events has occurred despite the
erformance of PCI on older patients and despite increased
se of intravenous GP IIb/IIIa inhibitors; 3) use of smaller
heaths, reduced intensity and duration of periprocedural
nticoagulation with heparin, and shorter procedures have
ontributed to the reduction in complications; 4) major
emoral bleeding complications are associated with pro-
onged hospital stay and markedly increased requirement for
Figure 3. Kaplan-Meier Curves Depicting Long-Term Survival of Patients W
Decreased survival was noted among patients with (A) any major bleeding co
major hematoma. Patient numbers at risk are presented below the ﬁgure.lood transfusion; and 5) major femoral bleeding compli- pations and blood transfusion are both associated with
ncreased mortality during long-term follow-up.
hanges in procedural technique and risk of complications.
he findings of the multivariate analysis suggest that risk of
ajor femoral bleeding complications might be minimized
y judicious use of smaller sheaths, careful titration of
ntraprocedural anticoagulation, and avoidance of post-
rocedure heparin infusions. Improved efficiency leading to
horter procedures might also reduce complications by
inimizing sheath dwell time (10,11). It is likely that the
assing out of favor of techniques such as directional
therectomy (that required larger sheath sizes and pro-
onged procedure times) have contributed to the decline in
he incidence of major vascular complications over the past
ecade. Incorporation of GP IIb/IIIa inhibitors into routine
ractice has been achieved, however, while bleeding com-
Without Major Bleeding Complications
tion, (B) retroperitoneal bleeding, (C) major external femoral bleeding, or (D)ith or
mplicalications have continued to decrease. The level of concom-
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208tant anticoagulation is an important determinant of the
bsolute bleeding risk associated with GP IIb/IIIa inhibitor
se (12–14), and it is likely that the effect of these agents on
omplication rates in this study was attenuated by a down-
ard trend in the intensity of anticoagulation.
Vascular closure devices are used infrequently in our
ractice (only 5% in Groups 2 and 3), and so the association
etween use of these devices and increased risk for major
emoral bleeding (OR 1.58, p  0.016) should be inter-
reted with caution. Nonetheless, previous studies have
uggested that such devices might increase risk of hema-
oma, pseudo-aneurysm formation, retroperitoneal hemor-
hage, and rare but catastrophic infectious and ischemic
omplications (15–20). Our findings re-emphasize the need
or large-scale randomized studies of these devices to
efinitively address these safety concerns.
utcome of major femoral bleeding complications. A num-
er of mechanisms might underlie the association between
ajor femoral bleeding, blood transfusion, and increased
ortality. Severe hemorrhage could directly increase risk of
eath by causing hemodynamic compromise, particularly in
atients with poor cardiac reserve or other severe comor-
idities. The need to stop antithrombotic therapies within
ours or days of PCI because of major bleeding could also
lay an indirect role, by increasing risk of ischemic coronary
omplications. Notably, accumulating data suggest a possi-
le direct link between blood transfusion and adverse
utcomes for a variety of critical illnesses and major surgical
rocedures (21,22). Pro-inflammatory and -thrombotic ef-
ects of red blood cell transfusion have been demonstrated
23), and use of a restrictive transfusion policy has been
Figure 4. Kaplan-Meier Curves Depicting Long-Term Survival of Patients
With or Without Blood Transfusion
Decreased long-term survival was noted among patients receiving blood
transfusion, with greatest risk observed among patients receiving blood
transfusion of 3 U. Patient numbers at risk are presented below the
ﬁgure.ssociated with improved outcomes for patients with criticalllness (24). Our data support the latter finding, because
ransfusions of 3 U were associated with worse outcomes
hen compared with transfusions of 1 to 2 U. Nevertheless,
t must be emphasized that a causal relationship between
ost-PCI blood transfusion and subsequent excess mortality
ill be impossible to establish outside of a randomized
linical trial comparing a traditional with a more restrictive
ransfusion policy. Moreover, it is possible that, despite the
ndings of our multivariate analysis, major femoral bleeding
nd blood transfusion might simply be surrogates for pa-
ients with more complex coronary disease and more exten-
ive comorbidities and that the associations with mortality
ight be due to unmeasured variables.
tudy limitations. Although the data were prospectively
athered, this was a retrospective study and is subject to the
imitations of this design. Outcomes are reported from a
ingle high-volume center using transfemoral access, and
ur use of vascular closure devices is low by comparison with
ome other centers. Therefore, our results might not be
pplicable to centers with lower volume or centers where use
f vascular closure devices or radial access is more frequent.
inally, our definition of major femoral bleeding complica-
ions did not incorporate measurement of pre- and post-
rocedure hemoglobin (used in the Thrombolysis In Myo-
ardial Infarction bleeding classification system). Therefore,
lthough stringent criteria for defining major femoral bleed-
ng—including the need for blood transfusion, vascular
urgery, and/or prolonged hospital stay—were used in this
tudy, caution should be exercised before making direct
omparisons between absolute bleeding risk observed in this
tudy and rates reported elsewhere.
onclusions
n this single-center study, we have noted a significant fall
n the incidence of major femoral bleeding complications
ver the past decade. These improvements have been
chieved without the use of bivalirudin and with relatively
nfrequent use of vascular closure devices. The association of
ajor femoral bleeding and blood transfusion with in-
reased long-term mortality remains a strong impetus for
urther improvements in access strategies for patients un-
ergoing PCI.
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